NCT06551051View on ClinicalTrials.gov

ADC-induced Neurotoxicity Treated With Duloxetine

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Solid Tumour
Interventions
DRUG

duloxetine

Patients were treated with duloxetine at a recommended dose of 40mg/day, increasing to a maximum dose of 60mg/day after seven days of non-significant discomfort.

Trial Locations (1)

200032

RECRUITING

Fudan University Cancer center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER